Immuron Limited

Management said FY2023 revenue exceeded budget by 92%, with growth in both Australia and the rest of the world, including the U.S. and Canada. The commercial business was described as “almost breakeven,” and the company said it had cash and cash equivalents of $22.1 million as of 30 July 2022 and essentially no debt. No EPS or gross margin figures were provided. Forward-looking, Immuron said it plans to file the Travelan IND with the FDA soon, initiate the first clinical trial in the first half of next year upon approval, and seek topline results before the end of that calendar year; it also plans to resolve the CampETEC clinical hold, continue evaluating IMM-529, and pursue organic growth plus M&A.

Steven Lydeamore framed the company as undervalued relative to its cash balance and operating assets, emphasizing two commercial products, multiple clinical programs, and what he called strong distribution relationships. His tone was upbeat but pragmatic: he repeatedly stressed execution, better communication with shareholders, and a willingness to use the balance sheet for both organic growth and acquisitions. He highlighted Travelan as the key near-term commercial and clinical driver, while saying the company is also reviewing new channels, new formulations, and possible portfolio additions.

No separate CFO appeared on the call, so the financial commentary came from the CEO. He cited cash and equivalents of $22.1 million, a market capitalization of $20.5 million as of 23 August, and “essentially no debt,” noting the company has a strong balance sheet to support organic growth and M&A. He also said the commercial side of the business was “almost breakeven” and that revenue had previously reached a run rate of around $3 million before the pandemic.

Analysts and shareholders focused heavily on valuation, share-price weakness, low market awareness, and poor liquidity. Management said it shared the frustration, argued the company should be worth more than cash given its products and pipeline, and promised more communication via quarterly webinars, newsletters, social media, broker meetings, and conference presentations. Questions also covered Travelan commercialization, Amazon stockouts, and the timing of FDA and European patent milestones; Lydeamore said Amazon was a temporary transition to a direct U.S. setup, Travelan’s IND filing was close, and one European patent had been approved while another was expected soon. On the failed acquisition and SARS-CoV-2 opportunity, he said the company was no longer pursuing that path or any lawsuit, and on NASH he said the program did not meet endpoints and would not be taken further.